Search clinical trials for: ENV-101 (taladegib)

Total 7349 results

University of Florida
Novatek

Not yet recruiting

Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment

Hepatocellular Carcinoma
Scioderm, Inc.
Amicus Therapeutics

Completed

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

United States
Abalonex, LLC

Not yet recruiting

Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury

Traumatic Brain Injury | Cerebral Edema
Benjamin Izar

Terminated

ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (ATX-101)

Leiomyosarcoma | Liposarcoma

United States
Flame Biosciences

Completed

A Bioavailability Study of FL-101 in Healthy Male and Female Subjects

Healthy Subjects

United States
Azure Biotech Inc.

Not yet recruiting

Open-Label Study of Vaginal AZU-101 in Postmenopausal Women

Postmenopausal Symptoms
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Bioavailability of IV and SC LBR-101

Bioavailability and Pharmacokinetics

United States
Gilead Sciences

Withdrawn

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
BlueWillow Biologics
Porton Biopharma Ltd.

Completed

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults (IN NE-rPA)

Anthrax

United States
Alaunos Therapeutics

Unknown

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Advanced Cancer

United States
Alaunos Therapeutics

Unknown

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Advanced Solid Tumors | Lymphomas

Canada
Desentum Oy

Completed

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

Birch Pollen Allergy

Finland
Healthpoint

Withdrawn

HP011-101, HP828-101, and Standard Care for Pressure Ulcers

Pressure Ulcers
Gilead Sciences

Completed

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Lantheus Medical Imaging

Completed

A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure

Heart Failure

United States
Ralexar Therapeutics, Inc.

Unknown

Study in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis Eczema

United States, Canada
Axovant Sciences Ltd.

Terminated

Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

Dementia With Lewy Bodies

United States, Canada, France, Italy, Netherlands, Spain, United Kingdom
National Institute of Allergy and Infectious Diseases...
Walter Reed Army Institute of Research (WRAIR); The Emmes Company, LLC; US Military... and other collaborators

Completed

A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya

HIV Infections

Kenya
Gilead Sciences

Terminated

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia

United States
International AIDS Vaccine Initiative
University of Rochester

Completed

A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers

HIV Infections | HIV

United States
Axovant Sciences Ltd.

Completed

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

Dementia With Lewy Bodies

United States, Canada, France, Italy, Netherlands, Spain, United Kingdom
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Hookipa Biotech GmbH
Centre for Vaccinology Ghent - CEVAC

Completed

Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

Cytomegalovirus Infection

Belgium
InQpharm Group

Completed

Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

Postprandial Heartburn

Germany
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin Lymphoma | Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)

Japan
Gilead Sciences

Completed

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Taivex Therapeutics Corporation

Recruiting

Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Taiwan
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

HIV Infections

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
University of Florence
Azienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaborators

Recruiting

Effectiveness and Tolerability of Eptinezumab (TACHIS)

Migraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura

Italy
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

HIV Infections

United States
First Affiliated Hospital Bengbu Medical College

Recruiting

Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)

Familial Hypercholesterolemia

China
Leiden University Medical Center

Recruiting

SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia (SGM-T1)

Colorectal Cancer | Image | Low Grade Dysplasia of Colon

Netherlands
CellinCells

Recruiting

Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

Atrophic Scar

Korea, Republic of
Perceive Biotherapeutics, Inc.

Recruiting

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

Australia, Israel
Isotech Ltd
Newcastle-upon-Tyne Hospitals NHS Trust

Recruiting

A Novel Device for the Treatment of Postural Hypotension - a Signal of Effectiveness Study.

Orthostatic Hypotension

United Kingdom
AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Hematologic Cancer

United States, Israel, Japan
Antengene (Hangzhou) Biologics Co., Ltd.

Recruiting

A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

China
Neurogene Inc.

Recruiting

Gene Therapy Study for Children With CLN5 Batten Disease (CLN5-200)

Neuronal Ceroid Lipofuscinosis CLN5

United States, United Kingdom
Heidelberg Pharma AG

Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Multiple Myeloma | Plasma Cell Disorder

United States, Germany, Poland, Hungary
Excision BioTherapeutics

Enrolling by invitation

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

HIV-1-infection

United States
CorrectSequence Therapeutics Co., Ltd
First Affiliated Hospital of Guangxi Medical University

Enrolling by invitation

CS-101 in Patients With β-thalassemia

Beta-Thalassemia

China
Tvardi Therapeutics, Incorporated
M.D. Anderson Cancer Center

Active, not recruiting

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Melanoma | Breast Cancer | Colorectal Cancer | Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Cancer | Head and Neck Squamous Cell Carcinoma | Hepatocellular Cancer

United States
Verve Therapeutics, Inc.

Active, not recruiting

A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | Heterozygous Familial Hypercholesterolemia

New Zealand, United Kingdom
Auris Medical AG

Completed

AM-101 in the Treatment of Post-Acute Tinnitus 2 (AMPACT2)

Tinnitus

Germany
Auris Medical, Inc.

Completed

AM-101 in the Treatment of Post-Acute Tinnitus 1 (AMPACT1)

Tinnitus

United States
Curis, Inc.

Completed

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

Tumors

United States

Search clinical trials for: ENV-101 (taladegib)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations